Halper Sadeh Investigates Rallybio Merger with Candid Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RLYB?
Source: Businesswire
- Merger Investigation Launched: Halper Sadeh LLC is investigating the merger between Rallybio Corporation and Candid Therapeutics, focusing on the fact that Rallybio shareholders will only own approximately 3.65% of the combined entity, which could impact shareholder rights.
- Legal Compliance Issues: The investigation concerns whether Rallybio's board violated federal securities laws and fiduciary duties by failing to secure the best possible deal for shareholders, potentially harming their interests.
- Sales Process Transparency: Halper Sadeh emphasizes that the fairness of the sales process and the absence of conflicts of interest are critical to the investigation, as any issues could affect the legality of the merger and shareholders' decision-making power.
- Shareholder Rights Protection: Halper Sadeh may seek increased consideration, additional disclosures, or other remedies on behalf of shareholders to ensure that Rallybio shareholders' legal rights are protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RLYB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RLYB
Wall Street analysts forecast RLYB stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 7.540
Low
1.00
Averages
1.00
High
1.00
Current: 7.540
Low
1.00
Averages
1.00
High
1.00
About RLYB
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rallybio and Candid Merge to Advance T-Cell Engager Therapies
- Merger Agreement: Rallybio has entered into a merger agreement with Candid Therapeutics, which is expected to enhance the company's portfolio of T-cell engager therapeutics for autoimmune diseases, thereby increasing its market competitiveness.
- Strong Financing Support: Candid has secured over $505 million in financing, and the combined entity is projected to have approximately $700 million in cash, providing a robust financial foundation to support operations through 2030 and multiple clinical milestones.
- Shareholder Structure Change: Post-merger, Rallybio shareholders are expected to own about 3.65% of the combined company, while Candid shareholders will hold approximately 96.35%, indicating Candid's dominant position in the merger.
- Outstanding Market Performance: Despite a broader market decline, Rallybio's stock surged 29.05% to $9.73, reaching a new 52-week high, reflecting a positive market reaction to the merger news.
See More
Halper Sadeh Investigates Rallybio Merger with Candid Therapeutics
- Merger Investigation Launched: Halper Sadeh LLC is investigating the merger between Rallybio Corporation and Candid Therapeutics, focusing on the fact that Rallybio shareholders will only own approximately 3.65% of the combined entity, which could impact shareholder rights.
- Legal Compliance Issues: The investigation concerns whether Rallybio's board violated federal securities laws and fiduciary duties by failing to secure the best possible deal for shareholders, potentially harming their interests.
- Sales Process Transparency: Halper Sadeh emphasizes that the fairness of the sales process and the absence of conflicts of interest are critical to the investigation, as any issues could affect the legality of the merger and shareholders' decision-making power.
- Shareholder Rights Protection: Halper Sadeh may seek increased consideration, additional disclosures, or other remedies on behalf of shareholders to ensure that Rallybio shareholders' legal rights are protected.
See More
Rallybio Acquires Candid Therapeutics, Shares Surge 27%
- Stock Surge: Rallybio (RLYB) shares rose approximately 27% in Monday morning trading, reflecting strong market confidence in the acquisition of Candid Therapeutics and the anticipated growth potential from this strategic move.
- Acquisition Approval: The boards of both companies have approved the acquisition, which is expected to close midyear, indicating Rallybio's proactive strategy to expand its product line and market share in the competitive biotech landscape.
- Financing Boost: A syndicate of healthcare institutional investors and mutual funds has agreed to invest $505 million in private financing for Candid, which not only supports Candid's R&D efforts but also enhances Rallybio's competitive position in the biopharmaceutical sector.
- New Company Focus: The combined entity will operate under the name Candid Therapeutics with the ticker “CDRX,” focusing on two phase 1 assets targeting multiple myeloma and non-Hodgkin's lymphoma, showcasing its strategic positioning in the treatment landscape.
See More
Rallybio Reports Positive Phase 1 Trial Results
- Clinical Trial Results: RLYB116 demonstrated complete and sustained inhibition of terminal complement at a 300 mg dose, indicating its potential as a new treatment option for complement-mediated diseases, which could significantly impact future therapeutic strategies.
- Safety Profile: The 150 mg and 300 mg once-weekly dosing of RLYB116 was well tolerated, with no gastrointestinal side effects reported among participants, and mild-to-moderate injection site reactions were consistent with other subcutaneously administered biologics, ensuring patient safety and compliance.
- Future Plans: Rallybio intends to initiate a Phase 2 clinical trial for immune platelet transfusion refractoriness in the second half of 2026, with topline data expected in 2027, which could enhance the company's market positioning and growth prospects in the healthcare sector.
- Market Performance Analysis: Despite the healthcare sector's moderate performance, Rallybio's shares have decreased by 17.97% over the past 12 months, currently trading at $4.50, indicating bearish momentum and reflecting market uncertainty regarding its near-term direction.
See More
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
See More
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
RLYB116 Study Progress: Rallybio has completed dosing for Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD study, with data expected in Q4 2025, targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
Financial Highlights: The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027, and reported a net income of $16 million for Q3 2025, a significant improvement from a net loss in the same period last year.
See More
Rallybio and Candid Merge to Advance T-Cell Engager Therapies
- Merger Agreement: Rallybio has entered into a merger agreement with Candid Therapeutics, which is expected to enhance the company's portfolio of T-cell engager therapeutics for autoimmune diseases, thereby increasing its market competitiveness.
- Strong Financing Support: Candid has secured over $505 million in financing, and the combined entity is projected to have approximately $700 million in cash, providing a robust financial foundation to support operations through 2030 and multiple clinical milestones.
- Shareholder Structure Change: Post-merger, Rallybio shareholders are expected to own about 3.65% of the combined company, while Candid shareholders will hold approximately 96.35%, indicating Candid's dominant position in the merger.
- Outstanding Market Performance: Despite a broader market decline, Rallybio's stock surged 29.05% to $9.73, reaching a new 52-week high, reflecting a positive market reaction to the merger news.
See More
Halper Sadeh Investigates Rallybio Merger with Candid Therapeutics
- Merger Investigation Launched: Halper Sadeh LLC is investigating the merger between Rallybio Corporation and Candid Therapeutics, focusing on the fact that Rallybio shareholders will only own approximately 3.65% of the combined entity, which could impact shareholder rights.
- Legal Compliance Issues: The investigation concerns whether Rallybio's board violated federal securities laws and fiduciary duties by failing to secure the best possible deal for shareholders, potentially harming their interests.
- Sales Process Transparency: Halper Sadeh emphasizes that the fairness of the sales process and the absence of conflicts of interest are critical to the investigation, as any issues could affect the legality of the merger and shareholders' decision-making power.
- Shareholder Rights Protection: Halper Sadeh may seek increased consideration, additional disclosures, or other remedies on behalf of shareholders to ensure that Rallybio shareholders' legal rights are protected.
See More
Rallybio Acquires Candid Therapeutics, Shares Surge 27%
- Stock Surge: Rallybio (RLYB) shares rose approximately 27% in Monday morning trading, reflecting strong market confidence in the acquisition of Candid Therapeutics and the anticipated growth potential from this strategic move.
- Acquisition Approval: The boards of both companies have approved the acquisition, which is expected to close midyear, indicating Rallybio's proactive strategy to expand its product line and market share in the competitive biotech landscape.
- Financing Boost: A syndicate of healthcare institutional investors and mutual funds has agreed to invest $505 million in private financing for Candid, which not only supports Candid's R&D efforts but also enhances Rallybio's competitive position in the biopharmaceutical sector.
- New Company Focus: The combined entity will operate under the name Candid Therapeutics with the ticker “CDRX,” focusing on two phase 1 assets targeting multiple myeloma and non-Hodgkin's lymphoma, showcasing its strategic positioning in the treatment landscape.
See More
Rallybio Reports Positive Phase 1 Trial Results
- Clinical Trial Results: RLYB116 demonstrated complete and sustained inhibition of terminal complement at a 300 mg dose, indicating its potential as a new treatment option for complement-mediated diseases, which could significantly impact future therapeutic strategies.
- Safety Profile: The 150 mg and 300 mg once-weekly dosing of RLYB116 was well tolerated, with no gastrointestinal side effects reported among participants, and mild-to-moderate injection site reactions were consistent with other subcutaneously administered biologics, ensuring patient safety and compliance.
- Future Plans: Rallybio intends to initiate a Phase 2 clinical trial for immune platelet transfusion refractoriness in the second half of 2026, with topline data expected in 2027, which could enhance the company's market positioning and growth prospects in the healthcare sector.
- Market Performance Analysis: Despite the healthcare sector's moderate performance, Rallybio's shares have decreased by 17.97% over the past 12 months, currently trading at $4.50, indicating bearish momentum and reflecting market uncertainty regarding its near-term direction.
See More
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
See More
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
RLYB116 Study Progress: Rallybio has completed dosing for Cohort 1 in the RLYB116 Phase 1 confirmatory PK/PD study, with data expected in Q4 2025, targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
Financial Highlights: The company generated $20 million from the sale of its interest in REV102, extending its cash runway through 2027, and reported a net income of $16 million for Q3 2025, a significant improvement from a net loss in the same period last year.
See More
